Stem definition | Drug id | CAS RN |
---|---|---|
angiotensin-converting enzyme inhibitors | 2712 | 87679-37-6 |
Dose | Unit | Route |
---|---|---|
2 | mg | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 1.06 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 10 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 0.25 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 12.50 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.17 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 0.26 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
April 26, 1996 | FDA | ABBVIE |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Lactic acidosis | 58.60 | 20.22 | 31 | 2755 | 33324 | 50569014 |
Paranoia | 55.40 | 20.22 | 21 | 2765 | 10327 | 50592011 |
Psychotic disorder | 52.20 | 20.22 | 25 | 2761 | 21787 | 50580551 |
Hallucination, auditory | 51.11 | 20.22 | 20 | 2766 | 10708 | 50591630 |
Focal segmental glomerulosclerosis | 44.14 | 20.22 | 11 | 2775 | 1330 | 50601008 |
Cerebellar haematoma | 39.93 | 20.22 | 8 | 2778 | 357 | 50601981 |
Endometrial ablation | 38.26 | 20.22 | 9 | 2777 | 854 | 50601484 |
Red blood cells urine positive | 36.22 | 20.22 | 11 | 2775 | 2764 | 50599574 |
White blood cells urine positive | 30.81 | 20.22 | 11 | 2775 | 4567 | 50597771 |
Bacterial test | 30.74 | 20.22 | 8 | 2778 | 1149 | 50601189 |
Vaginal discharge | 29.36 | 20.22 | 11 | 2775 | 5229 | 50597109 |
Hyperaesthesia | 27.88 | 20.22 | 12 | 2774 | 8161 | 50594177 |
Urine abnormality | 27.50 | 20.22 | 11 | 2775 | 6227 | 50596111 |
Acute kidney injury | 25.19 | 20.22 | 45 | 2741 | 228013 | 50374325 |
Cardiogenic shock | 23.21 | 20.22 | 13 | 2773 | 15586 | 50586752 |
Organising pneumonia | 23.08 | 20.22 | 9 | 2777 | 4765 | 50597573 |
Dorsal ramus syndrome | 21.54 | 20.22 | 4 | 2782 | 119 | 50602219 |
Palindromic rheumatism | 21.31 | 20.22 | 4 | 2782 | 126 | 50602212 |
Angioedema | 20.88 | 20.22 | 17 | 2769 | 37659 | 50564679 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Oesophageal obstruction | 77.44 | 18.89 | 16 | 3271 | 405 | 29570835 |
Bezoar | 66.84 | 18.89 | 16 | 3271 | 803 | 29570437 |
Arterial disorder | 38.61 | 18.89 | 11 | 3276 | 1092 | 29570148 |
Oesophageal haemorrhage | 29.41 | 18.89 | 9 | 3278 | 1144 | 29570096 |
Reading disorder | 27.52 | 18.89 | 7 | 3280 | 451 | 29570789 |
Jugular vein distension | 25.37 | 18.89 | 7 | 3280 | 618 | 29570622 |
Waist circumference increased | 24.09 | 18.89 | 7 | 3280 | 745 | 29570495 |
Body mass index increased | 23.39 | 18.89 | 7 | 3280 | 825 | 29570415 |
Bronchial wall thickening | 21.77 | 18.89 | 7 | 3280 | 1045 | 29570195 |
Eosinophil count increased | 21.05 | 18.89 | 12 | 3275 | 7357 | 29563883 |
Dysgraphia | 20.75 | 18.89 | 8 | 3279 | 2030 | 29569210 |
Hypopnoea | 20.56 | 18.89 | 7 | 3280 | 1247 | 29569993 |
Wrong product administered | 20.40 | 18.89 | 10 | 3277 | 4521 | 29566719 |
Lung opacity | 19.85 | 18.89 | 7 | 3280 | 1385 | 29569855 |
Cough | 19.21 | 18.89 | 43 | 3244 | 126684 | 29444556 |
Hypotension | 19.13 | 18.89 | 56 | 3231 | 194298 | 29376942 |
Chest X-ray abnormal | 18.98 | 18.89 | 9 | 3278 | 3785 | 29567455 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Oesophageal obstruction | 71.12 | 17.88 | 16 | 5458 | 803 | 64492455 |
Lactic acidosis | 59.54 | 17.88 | 46 | 5428 | 61364 | 64431894 |
Bezoar | 55.40 | 17.88 | 16 | 5458 | 2187 | 64491071 |
Reading disorder | 39.84 | 17.88 | 10 | 5464 | 803 | 64492455 |
Paranoia | 37.48 | 17.88 | 21 | 5453 | 16331 | 64476927 |
Arterial disorder | 36.18 | 17.88 | 11 | 5463 | 1794 | 64491464 |
Endometrial ablation | 35.05 | 17.88 | 9 | 5465 | 792 | 64492466 |
Hallucination, auditory | 34.12 | 17.88 | 20 | 5454 | 16919 | 64476339 |
Cerebellar haematoma | 32.58 | 17.88 | 8 | 5466 | 587 | 64492671 |
Hyperkalaemia | 31.80 | 17.88 | 41 | 5433 | 101088 | 64392170 |
Psychotic disorder | 31.54 | 17.88 | 25 | 5449 | 34553 | 64458705 |
Acute kidney injury | 31.09 | 17.88 | 96 | 5378 | 449144 | 64044114 |
Oesophageal haemorrhage | 28.98 | 17.88 | 9 | 5465 | 1575 | 64491683 |
Vaginal discharge | 27.62 | 17.88 | 11 | 5463 | 3986 | 64489272 |
Bacterial test | 26.97 | 17.88 | 8 | 5466 | 1199 | 64492059 |
Red blood cells urine positive | 26.41 | 17.88 | 11 | 5463 | 4467 | 64488791 |
Hypoglycaemia | 26.02 | 17.88 | 35 | 5439 | 89857 | 64403401 |
Dysgraphia | 25.55 | 17.88 | 10 | 5464 | 3461 | 64489797 |
White blood cells urine positive | 24.43 | 17.88 | 11 | 5463 | 5387 | 64487871 |
Cardiogenic shock | 22.45 | 17.88 | 20 | 5454 | 32407 | 64460851 |
Jugular vein distension | 22.05 | 17.88 | 7 | 5467 | 1315 | 64491943 |
Waist circumference increased | 21.80 | 17.88 | 7 | 5467 | 1364 | 64491894 |
Urine abnormality | 21.19 | 17.88 | 11 | 5463 | 7351 | 64485907 |
Body mass index increased | 20.83 | 17.88 | 7 | 5467 | 1572 | 64491686 |
Bronchial wall thickening | 19.54 | 17.88 | 7 | 5467 | 1900 | 64491358 |
Cough | 19.40 | 17.88 | 63 | 5411 | 302085 | 64191173 |
Libido decreased | 19.30 | 17.88 | 9 | 5465 | 4775 | 64488483 |
Coagulopathy | 18.82 | 17.88 | 18 | 5456 | 31902 | 64461356 |
Rales | 18.31 | 17.88 | 13 | 5461 | 15216 | 64478042 |
Hyperaesthesia | 18.03 | 17.88 | 11 | 5463 | 10003 | 64483255 |
Combined pulmonary fibrosis and emphysema | 18.03 | 17.88 | 3 | 5471 | 29 | 64493229 |
None
Source | Code | Description |
---|---|---|
ATC | C09AA10 | CARDIOVASCULAR SYSTEM AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ACE INHIBITORS, PLAIN ACE inhibitors, plain |
ATC | C09BB10 | CARDIOVASCULAR SYSTEM AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ACE INHIBITORS, COMBINATIONS ACE inhibitors and calcium channel blockers |
FDA MoA | N0000000181 | Angiotensin-converting Enzyme Inhibitors |
FDA EPC | N0000175562 | Angiotensin Converting Enzyme Inhibitor |
MeSH PA | D000806 | Angiotensin-Converting Enzyme Inhibitors |
MeSH PA | D000959 | Antihypertensive Agents |
MeSH PA | D002317 | Cardiovascular Agents |
MeSH PA | D004791 | Enzyme Inhibitors |
MeSH PA | D011480 | Protease Inhibitors |
CHEBI has role | CHEBI:35457 | ACE inhibitor |
CHEBI has role | CHEBI:35674 | antihypertensive drugs |
CHEBI has role | CHEBI:50266 | Prodrugs |
CHEBI has role | CHEBI:49103 | drug metabolites |
CHEBI has role | CHEBI:76967 | human xenobiotic metabolites |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Hypertensive disorder | indication | 38341003 | DOID:10763 |
Chronic heart failure | indication | 48447003 | |
Left ventricular cardiac dysfunction | indication | 429589006 | |
Atrial fibrillation | off-label use | 49436004 | DOID:0060224 |
Diabetic renal disease | off-label use | 127013003 | |
Diastolic heart failure | off-label use | 418304008 | DOID:9775 |
Nondiabetic Proteinuric Nephropathy | off-label use | ||
Hyperkalemia | contraindication | 14140009 | |
Ventricular tachycardia | contraindication | 25569003 | |
Complete atrioventricular block | contraindication | 27885002 | |
Acute cerebrovascular insufficiency | contraindication | 29322000 | |
Sick sinus syndrome | contraindication | 36083008 | DOID:13884 |
Immunosuppression | contraindication | 38013005 | |
Angioedema | contraindication | 41291007 | DOID:1558 |
Low cardiac output syndrome | contraindication | 44088000 | |
Low blood pressure | contraindication | 45007003 | |
Bradycardia | contraindication | 48867003 | |
Lown-Ganong-Levine syndrome | contraindication | 55475008 | DOID:13087 |
Aortic valve stenosis | contraindication | 60573004 | DOID:1712 |
Wolff-Parkinson-White pattern | contraindication | 74390002 | DOID:384 |
Duchenne muscular dystrophy | contraindication | 76670001 | DOID:11723 |
Transplantation | contraindication | 77465005 | |
Chronic idiopathic constipation | contraindication | 82934008 | |
Hereditary angioneurotic edema | contraindication | 82966003 | DOID:14735 |
Left heart failure | contraindication | 85232009 | |
Cardiogenic shock | contraindication | 89138009 | |
Hyponatremia | contraindication | 89627008 | |
Kidney disease | contraindication | 90708001 | DOID:557 |
Myasthenia gravis | contraindication | 91637004 | DOID:437 |
Disorder of connective tissue | contraindication | 105969002 | DOID:65 |
Liver function tests abnormal | contraindication | 166603001 | |
Second degree atrioventricular block | contraindication | 195042002 | |
Hypertrophic cardiomyopathy | contraindication | 233873004 | DOID:11984 |
Disease of liver | contraindication | 235856003 | DOID:409 |
Pregnancy, function | contraindication | 289908002 | |
Renal artery stenosis | contraindication | 302233006 | |
Neutropenic disorder | contraindication | 303011007 | DOID:1227 |
Bone marrow depression | contraindication | 307762000 | |
Neuromuscular Transmission Deficiency | contraindication | ||
Hemodialysis with High-Flux Membrane | contraindication | ||
First Degree Atrioventricular Heart Block | contraindication |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 3.23 | acidic |
pKa2 | 5.77 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Angiotensin-converting enzyme | Enzyme | INHIBITOR | IC50 | 8.12 | WOMBAT-PK | CHEMBL |
ID | Source |
---|---|
4020971 | VUID |
N0000148444 | NUI |
D00383 | KEGG_DRUG |
4020971 | VANDF |
C0076891 | UMLSCUI |
CHEBI:9649 | CHEBI |
CHEBI:141521 | CHEBI |
X93 | PDB_CHEM_ID |
CHEMBL1519 | ChEMBL_ID |
DB00519 | DRUGBANK_ID |
C052035 | MESH_SUPPLEMENTAL_RECORD_UI |
5484727 | PUBCHEM_CID |
6453 | IUPHAR_LIGAND_ID |
C061095 | MESH_SUPPLEMENTAL_RECORD_UI |
6455 | IUPHAR_LIGAND_ID |
5746 | INN_ID |
87679-71-8 | SECONDARY_CAS_RN |
1T0N3G9CRC | UNII |
5464097 | PUBCHEM_CID |
DB14209 | DRUGBANK_ID |
1546379 | RXNORM |
107488 | MMSL |
5448 | MMSL |
5606 | MMSL |
5642 | MMSL |
d04008 | MMSL |
004452 | NDDF |
108562001 | SNOMEDCT_US |
386871006 | SNOMEDCT_US |
C0165477 | UMLSCUI |
CHEMBL1201387 | ChEMBL_ID |
6370 | INN_ID |
RR6866VL0O | UNII |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Trandolapril | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42806-052 | TABLET | 1 mg | ORAL | ANDA | 18 sections |
Trandolapril | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42806-053 | TABLET | 2 mg | ORAL | ANDA | 18 sections |
Trandolapril | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42806-054 | TABLET | 4 mg | ORAL | ANDA | 18 sections |
Trandolapril | Human Prescription Drug Label | 1 | 50090-4120 | TABLET | 2 mg | ORAL | ANDA | 21 sections |
Trandolapril | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-4128 | TABLET | 1 mg | ORAL | ANDA | 19 sections |
Mavik | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-5099 | TABLET | 4 mg | ORAL | NDA | 20 sections |
Tarka | HUMAN PRESCRIPTION DRUG LABEL | 2 | 54868-5311 | TABLET, FILM COATED, EXTENDED RELEASE | 2 mg | ORAL | NDA | 20 sections |
Tarka | HUMAN PRESCRIPTION DRUG LABEL | 2 | 54868-5320 | TABLET, FILM COATED, EXTENDED RELEASE | 4 mg | ORAL | NDA | 20 sections |
Tarka | HUMAN PRESCRIPTION DRUG LABEL | 2 | 54868-5548 | TABLET, FILM COATED, EXTENDED RELEASE | 2 mg | ORAL | NDA | 20 sections |
Trandolapril | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-6061 | TABLET | 4 mg | ORAL | ANDA | 14 sections |
Trandolapril | Human Prescription Drug Label | 1 | 57237-089 | TABLET | 1 mg | ORAL | ANDA | 20 sections |
Trandolapril | Human Prescription Drug Label | 1 | 57237-090 | TABLET | 2 mg | ORAL | ANDA | 20 sections |
Trandolapril | Human Prescription Drug Label | 1 | 57237-091 | TABLET | 4 mg | ORAL | ANDA | 20 sections |
Trandolapril | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-8003 | TABLET | 2 mg | ORAL | ANDA | 18 sections |
Trandolapril | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-8390 | TABLET | 4 mg | ORAL | ANDA | 20 sections |
Trandolapril | Human Prescription Drug Label | 1 | 65862-164 | TABLET | 1 mg | ORAL | ANDA | 20 sections |
Trandolapril | Human Prescription Drug Label | 1 | 65862-165 | TABLET | 2 mg | ORAL | ANDA | 20 sections |
Trandolapril | Human Prescription Drug Label | 1 | 65862-166 | TABLET | 4 mg | ORAL | ANDA | 20 sections |
Trandolapril | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68151-0757 | TABLET | 1 mg | ORAL | ANDA | 18 sections |
Trandolapril | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68180-566 | TABLET | 1 mg | ORAL | ANDA | 18 sections |
Trandolapril | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68180-567 | TABLET | 2 mg | ORAL | ANDA | 18 sections |
Trandolapril | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68180-568 | TABLET | 4 mg | ORAL | ANDA | 18 sections |
Trandolapril | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68258-6100 | TABLET | 4 mg | ORAL | ANDA | 20 sections |
Trandolapril and Verapamil Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 2 | 68462-294 | TABLET, FILM COATED, EXTENDED RELEASE | 1 mg | ORAL | ANDA | 20 sections |
Trandolapril and Verapamil Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 2 | 68462-295 | TABLET, FILM COATED, EXTENDED RELEASE | 2 mg | ORAL | ANDA | 20 sections |
Trandolapril and Verapamil Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 2 | 68462-296 | TABLET, FILM COATED, EXTENDED RELEASE | 2 mg | ORAL | ANDA | 20 sections |
Trandolapril and Verapamil Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 2 | 68462-329 | TABLET, FILM COATED, EXTENDED RELEASE | 4 mg | ORAL | ANDA | 20 sections |
Trandolapril | Human Prescription Drug Label | 1 | 71335-1431 | TABLET | 2 mg | ORAL | ANDA | 20 sections |